https://www.selleckchem.com/pr....oducts/ganetespib-st
f CAR-T cells and combined with HSCT after infusion are independent factors for improving the prognosis of the patients. Anti-cluster of classification (CD) 19 CAR-T cell therapy is safe and efficacious against relapsed or refractory B-ALL in children. Reducing the tumor burden before infusion of CAR-T cells and combined with HSCT after infusion are independent factors for improving the prognosis of the patients. To explore the influence of nm23-H1 on the proliferation and apoptosis of glioma cells and the mechanism of actio
Like
Comment
Share
